PRMT5 inhibitors and uses thereof

1. A method of treating a disorder comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula I:

or a pharmaceutically acceptable salt thereof,

wherein

represents a single or double bond;

R 1 is hydrogen, R z , or —C(O)R z , wherein R z is C 1-6 alkyl;

L is —O—, —N(R)—, —C(R 2 )(R 3 )—, —O—CR 2 R 3 —, —N(R)—CR 2 R 3 —, —O—CR 2 R 3 —O—, —N(R)—CR 2 R 3 —O—, —N(R)—CR 2 R 3 —N(R)—, —O—CR 2 R 3 —N(R)—, —CR 2 R 3 —O—, —CR 2 R 3 —N(R)—, —O—CR 2 R 3 —CR 9 R 10 —, —N(R)—CR 2 R 3 —CR 9 R 10 —, —CR 2 R 3 —CR 9 R 10 —O—, —CR 2 R 3 —CR 9 R 10 —N(R)—, or —CR 2 R 3 —CR 9 R 10 —;

each R is independently hydrogen or C 1-6 aliphatic;

R 2 and R 3 are independently selected from the group consisting of hydrogen, halo, and aliphatic;

Ring A is phenyl;

R 4 is -L 1 -Cy;

L 1 is a bond;

Cy is an, monocyclic aromatic ring selected from the group consisting of phenyl and 6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

R 5 , R 6 , R 7 , and R 8 are independently hydrogen, halo, or aliphatic;

R 9 and R 10 are independently selected from the group consisting of hydrogen, halo, and -aliphatic;

each R y is independently selected from the group consisting of halo, —CN, —NO 2 , and aliphatic;

each R x is independently selected from the group consisting of halo, —CN, aliphatic, —OR′, and —N(R″) 2 ;

R′ is hydrogen or aliphatic;

each R″ is independently hydrogen or aliphatic, or two R″ are taken together with their intervening atoms to form a heterocyclic ring;

n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, as valency permits;

m is 0, 1, 2, 3, 4, 5, 6, 7, or 8, as valency permits; and

p is 1;

wherein each instance of aliphatic is independently a C 1-4 alkyl, alkenyl, or alkynyl;

wherein the disorder is cancer, a metabolic disorder, or a blood disorder;

wherein the cancer is breast cancer, esophageal cancer, bladder cancer, lymphoma, medulloblastoma, rectum adenocarcinoma, colon adenocarcinoma, gastric cancer, liver cancer, adenoid cystic carcinoma, lung adenocarcinoma, head and neck squamous cell carcinoma, brain cancer, hepatocellular carcinoma, renal cell carcinoma, oligodendroglioma, ovarian clear cell carcinoma, ovarian serous cystadenocarcinoma, hematopoietic cancer, lung cancer, prostate cancer, melanoma, or pancreatic cancer;

wherein the metabolic disorder is diabetes or obesity; and

wherein the blood disorder is a hemoglobinopathy.

2. The method of claim 1 , wherein L is —O—.

3. The method of claim 1 , wherein R 1 is hydrogen.

4. The method of claim 1 , wherein n is 0, 1, or 2.

5. The method of claim 1 , wherein L is —N(R)— or —C(R 2 )(R 3 )—, and R, R 2 , and R 3 are each hydrogen.

6. The method of claim 1 , wherein the compound is of formula V:

or a pharmaceutically acceptable salt thereof, wherein X 1 , X 2 , X 3 , and X 4 are independently selected from the group consisting of CH and CR y .

7. The method of claim 1 , wherein Cy is optionally substituted phenyl.

8. The method of claim 1 , wherein Cy is an optionally substituted 6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

9. The method of claim 1 , wherein the compound is selected from the group consisting of

and pharmaceutically acceptable salts thereof.

10. The method of claim 1 , wherein the hemoglobinopathy is β-thalessemia or sickle cell anemia.

11. The method of claim 1 , wherein the compound is of formula (I′):

or a pharmaceutically acceptable salt thereof,

wherein:

R 1 is hydrogen or C 1-4 alkyl;

L is —O—, —N(R)—, —C(R 2 )(R 3 )—, —CR 2 R 3 —O—, or —CR 2 R 3 —N(R)—;

each R is independently hydrogen or C 1-4 alkyl;

R 2 and R 3 are independently selected from the group consisting of hydrogen, halo, and C 1-4 alkyl;

Ring A is phenyl;

R 4 is -L 1 -Cy;

L 1 is a bond;

Cy is an, monocyclic, aromatic ring selected from the group consisting of phenyl and 6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

R 5 , R 6 , R 7 , and R 8 are independently hydrogen, halo, or C 1-4 alkyl;

each R y is independently selected from the group consisting of halo and C 1-4 alkyl;

each R x is independently selected from the group consisting of halo, —CN, C 1-4 alkyl, —OR′, and —N(R″) 2 ;

R′ is hydrogen or C 1-4 alkyl;

each R″ is independently hydrogen or C 1-4 alkyl, or two R″ are taken together with their intervening atoms to form a heterocyclic ring;

n is 0, 1, 2, or 3, as valency permits;

m is 0, 1, 2, or 3 as valency permits; and

p is 1.

12. The method of claim 11 , wherein L is —O— or —N(R)—.

13. The method of claim 11 , wherein R 1 is hydrogen.

14. The method of claim 11 , wherein n is 0.

15. The method of claim 11 , wherein R 5 , R 6 , R 7 , and R 8 are each hydrogen.

16. The method of claim 11 , wherein the compound is of formula V:

or a pharmaceutically acceptable salt thereof, wherein X 1 , X 2 , X 3 , and X 4 are independently selected from the group consisting of CH and CR y .

17. The method of claim 11 , wherein Cy is phenyl.

18. The method of claim 11 , wherein Cy is 6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

19. The method of claim 18 , wherein Cy is pyridyl or pyrimidyl.

20. The method of claim 6 , wherein Cy is pyridyl or pyrimidyl.

21. The method of claim 1 , wherein the disorder is cancer, and wherein the cancer is breast cancer, bladder cancer, lymphoma, or brain cancer.

22. A compound selected from the group consisting of:

and pharmaceutically acceptable salts thereof.